Mark this date:
On March 31st, 2026...
The biggest scam in the history of gold markets will be exposed...
It's the math that keeps bankers up at night...
The gold chart that has Wall Street shaking in its loafers...
That's the day the public will see that their gold ETFs are nothing but paper...
The rush from ETFs to real assets will be unlike anything we've seen in 300 years.
One stock on the receiving end of this epic transfer, is set to explode 1,000% as ETF holders could get wiped out.
This isn't a hunch - it's math.
See all the evidence for yourself right here and take your position before it's too late.
"The Buck Stops Here,"
Dylan Jovine
NVIDIA's AI Boom Isn't Slowing After Blowout Q4
Written by Thomas Hughes. Posted: 2/26/2026.
Key Points
- NVIDIA's fourth-quarter results reveal that its growth is far from slowing, continuing to accelerate faster than expected.
- Analysts responded favorably to the news, lifting price targets and pointing to the high end of the range and another solid double-digit upside.
- Institutional trends reveal this stock was aggressively accumulated in early 2026, highlighting its value to investors.
- Special Report: [Sponsorship-Ad-6-Format3]
NVIDIA’s (NASDAQ: NVDA) Q4 earnings release for its fiscal 2026 (FY2026) shows that its AI growth is far from slowing. While concerns about AI spending and disruption persist, NVIDIA’s revenue continues to grow at hyper-growth levels, and guidance points to more of the same.
Whether AI is a bubble or not, cash is still flowing into the market and the peaks may not yet have been reached. What this means for NVIDIA investors is that revenue is likely to remain at or above current levels for the next few quarters — and possibly several years — underpinning robust cash flow, enabling reinvestment in next‑generation technologies, acquisitions to expand the business, and capital returns to drive shareholder value.
NVIDIA’s Wow-Quarter Reveals Acceleration in Critical Markets
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
NVIDIA’s Q4 reveals acceleration in critical markets, with revenue of $68.3 billion outpacing MarketBeat’s reported consensus by 300 basis points. Strength was broad-based, with gains in automotive and gaming aligning with signs of an emergent supercycle reported by industrial chipmakers.
Data Center, the company’s most critical segment, grew 22% sequentially and 75% year-over-year (YOY), driven by demand for high-performance computing and AI infrastructure. It now accounts for more than 90% of revenue and is expected to remain strong in the coming quarters. Professional Visualization grew 158% YOY, Gaming rose 48%, and Automotive increased 6%.
Margin news was also robust, supporting the analysts’ stock-price outlook. The company experienced improved operating leverage across the income statement, resulting in $1.62 in adjusted EPS—nearly a dime above estimates.
Earnings outperformed revenue growth by roughly 500 basis points, leaving adjusted EPS up 82% compared with a 73% increase in the top line. Looking ahead, margins are expected to contract only slightly: Q1 FY2027 adjusted gross margin is forecast to decline by about 20 basis points versus Q4.
As strong as the revenue and earnings growth was, the guidance is stronger. The company forecasts $78 billion in Q1 FY2027 revenue, up $10 billion (14.7% sequentially) and 77% YOY, excluding China. Including China — if approvals for sales to China are granted — growth would be even stronger. Other key details include cash flow and free cash flow (FCF), which approached $35 billion (just over half of Q4 revenue) and are expected to remain healthy over the coming year.
Analysts Highlight 50% Upside Potential for NVIDIA’s Stock in 2026
The analyst response to NVIDIA’s report and guidance was broadly bullish, affirming the uptrend and forecasting at least 35% upside from late-February support levels.
While consensus was previously pegged near $268, the handful of updates and revisions issued immediately after the release included price-target increases and bullish affirmations. No reductions were logged: the consensus of new targets sits near $300, with the high end around $400.
A move to the consensus target would be sufficient to set a fresh all-time high, breaking the stock out of its recent consolidation range. Technical indicators suggest a minimum move to the $270–$280 area, while a full bull case could see considerably higher gains. Momentum indicators, including stochastic and MACD, align with trend-following entries that could sustain upward price movement.
Analyst and institutional sentiment trends point to a broad-based rally. MarketBeat tracks more than 50 analysts; sentiment is pegged at Buy with a 96% buy-side bias. Institutions aggressively accumulated in early 2026, having built positions throughout 2025 and ending Q1 2026 owning more than 65% of the stock. In early Q1, the balance was more than $4 bought for each $1 sold, providing solid support and a strong tailwind.
NVIDIA’s Balance Sheet Is a Great Reason to Own It
Market drivers and macro concerns aside, NVIDIA’s business is healthy and appears well-positioned for the next several quarters thanks to robust cash generation. That strength shows up on the balance sheet, which reflects higher cash, assets, and equity despite aggressive investments, capital returns, and acquisitions. Cash, up roughly 50% year-over-year at fiscal year-end, topped $60 billion, driving a greater-than-50% increase in current assets (including receivables and inventory) and a nearly 100% rise in total assets.
Equity, a key measure of shareholder value, nearly doubled to $157 billion, while leverage remains low. NVIDIA does carry debt, but it declined over the year and is more than offset by cash. That cash balance leaves the company with a net-cash position relative to total liabilities, putting it in an enviable position to continue executing its strategy and building shareholder value.
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
Authored by Chris Markoch. Article Published: 2/19/2026.
Key Points
- CRISPR Therapeutics’ Q4 reaction reflects longer-term optimism despite weak reported revenue tied to launch economics.
- CASGEVY adoption is a key narrative driver, but profitability hinges on timing, revenue-sharing mechanics, and pipeline progress.
- With substantial cash on hand, the near-term question is technical/entry risk, while the long-term question is execution.
- Special Report: [Sponsorship-Ad-6-Format3]
CRISPR Therapeutics AG (NASDAQ: CRSP) stock jumped more than 12% after the gene-editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that reaction may seem surprising.
The company posted a larger-than-expected net loss and revenue that fell far short of estimates.
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
But CRISPR is a long-term story still in the early innings. The company has moved beyond proof of concept, yet investors will need patience — the transition into a mature growth phase is likely one to two years away.
Putting the Earnings Report Into Context
In December 2023, CRISPR received U.S. Food & Drug Administration (FDA) approval for CASGEVY, the company's flagship gene therapy for sickle cell disease and beta thalassemia. It was the first CRISPR/Cas9 gene-editing therapy approved by the FDA.
CRSP stock, however, is down roughly 19% since that announcement. Part of that decline reflects growth expectations already priced into the share price; another factor is the revenue structure of CRISPR's partnership with Vertex Pharmaceuticals Inc. (NASDAQ: VRTX).
The collaboration was critical to getting CASGEVY approved, but it includes a revenue-sharing arrangement under which CRISPR recognizes revenue only after Vertex recoups certain launch and manufacturing costs. So, while CASGEVY generated $54 million in the most recent quarter, CRISPR reported quarterly revenue of just $0.86 million.
That dynamic helps frame the investment thesis for CRSP. On one hand, more patients are receiving CASGEVY. On the other, operating losses are increasing as the company advances additional pipeline candidates. A key metric to watch is the company's cash and investment balance of about $1.9 billion, which should provide a runway of roughly three to four years.
The Pipeline Holds the Key
Even if CASGEVY adoption accelerates, there are structural headwinds. These are one-time, high-cost treatments that typically require payment arrangements stretching out revenue recognition.
That's why, as with most biotechnology companies, CRISPR's pipeline is central to the long-term case. One of the more promising candidates is CTX611, currently in clinical trials to prevent pathologic blood clots (such as those from stroke or deep vein thrombosis). The treatment targets Factor XI, which is involved in harmful clot formation while sparing normal hemostasis for routine cuts.
CRISPR is testing CTX611 (SRSD107) in a Phase 2 trial for total knee arthroplasty (TKA), where post-operative clots are a common complication.
Early human data show CTX611 has been well tolerated and produced strong, durable effects, with the potential for dosing as infrequently as every six weeks via the company's siRNA platform, which also enables designed reversibility.
If larger trials confirm lower bleeding risk along with convenient, infrequent dosing, CTX611 could access a roughly $20 billion global anticoagulation market and become a meaningful growth driver.
One Thing to Check Before Getting Involved With CRSP Stock
Analyst sentiment aligns with a "wait-and-see" view for CRISPR Therapeutics. The consensus rating is Hold, with two Sell ratings included. That mix features Morgan Stanley's recent Underweight, which came paired with a $33 price target — a level that would sit within roughly 10% of the stock's 52-week low.
While the chart may not immediately suggest such a decline, a move to that target would imply about a 37% drop from recent levels. As of this writing, CRSP was trading near its 200-day moving average, which has acted as support since November; a confirmed break below that level could invite additional selling.
CRSP Stock Is One to Own, Not Trade
It's been a volatile ride for long-term CRSP shareholders, but the stock has delivered substantial gains. Since the company's 2016 IPO, investors have seen a total return of more than 277%, a figure that includes the 2020–2021 period when speculative momentum pushed the shares higher.
The takeaway: CRISPR Therapeutics is progressing on its pipeline, but not as quickly as some investors might hope. CRSP may not suit short-term traders seeking rapid price moves, but it could fit long-term investors who can tolerate volatility and are positioned for potential significant gains by the end of the decade.
This message is a paid advertisement provided by Behind the Markets, a third-party advertiser of MarketBeat. Why was I sent this email?.
If you have questions or concerns about your account, feel free to email our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, South Dakota 57103-7078. USA..
Post a Comment
Post a Comment